Anti-Retroviral Agents: Agents used to treat RETROVIRIDAE INFECTIONS.HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).Anti-HIV Agents: Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.Antiretroviral Therapy, Highly Active: Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.CD4 Lymphocyte Count: The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.HIV-1: The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.Viral Load: The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.Immune Reconstitution Inflammatory Syndrome: Exuberant inflammatory response towards previously undiagnosed or incubating opportunistic pathogens. It is frequently seen in AIDS patients following HAART.Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.Cytomegalovirus Retinitis: Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in AIDS patients and can cause blindness.AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.Medication Adherence: Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency.HIV Protease Inhibitors: Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.HIV Seropositivity: Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Zambia: A republic in southern Africa, south of DEMOCRATIC REPUBLIC OF THE CONGO and TANZANIA, and north of ZIMBABWE. Its capital is Lusaka. It was formerly called Northern Rhodesia.CD4-CD8 Ratio: Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that express the CD8 ANTIGEN. This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS.Nigeria: A republic in western Africa, south of NIGER between BENIN and CAMEROON. Its capital is Abuja.AIDS Dementia Complex: A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40)South Africa: A republic in southern Africa, the southernmost part of Africa. It has three capitals: Pretoria (administrative), Cape Town (legislative), and Bloemfontein (judicial). Officially the Republic of South Africa since 1960, it was called the Union of South Africa 1910-1960.Uganda: A republic in eastern Africa, south of SUDAN and west of KENYA. Its capital is Kampala.Infectious Disease Transmission, Vertical: The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding.Ethiopia: An independent state in eastern Africa. Ethiopia is located in the Horn of Africa and is bordered on the north and northeast by Eritrea, on the east by Djibouti and Somalia, on the south by Kenya, and on the west and southwest by Sudan. Its capital is Addis Ababa.Malawi: A republic in southern Africa east of ZAMBIA and MOZAMBIQUE. Its capital is Lilongwe. It was formerly called Nyasaland.Lymphoma, AIDS-Related: B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.Treatment Failure: A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.Drug Resistance, Viral: The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.Reverse Transcriptase Inhibitors: Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.Kenya: A republic in eastern Africa, south of ETHIOPIA, west of SOMALIA with TANZANIA to its south, and coastline on the Indian Ocean. Its capital is Nairobi.CD8-Positive T-Lymphocytes: A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Antitubercular Agents: Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.Pregnancy Complications, Infectious: The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION.Viremia: The presence of viruses in the blood.Virus Replication: The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM.Patient Compliance: Voluntary cooperation of the patient in following a prescribed regimen.Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.RNA, Viral: Ribonucleic acid that makes up the genetic material of viruses.Simian Acquired Immunodeficiency Syndrome: Acquired defect of cellular immunity that occurs naturally in macaques infected with SRV serotypes, experimentally in monkeys inoculated with SRV or MASON-PFIZER MONKEY VIRUS; (MPMV), or in monkeys infected with SIMIAN IMMUNODEFICIENCY VIRUS.Drug Therapy, Combination: Therapy with two or more separate preparations given for a combined effect.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Antiviral Agents: Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.Cross-Sectional Studies: Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.IndiaRetrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Longitudinal Studies: Studies in which variables relating to an individual or group of individuals are assessed over a period of time.Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.

*  Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) - Full...

Anti-Retroviral Agents. HIV Protease Inhibitors. Protease Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Anti-HIV Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome P-450 Enzyme Inhibitors ... Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir). ... Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) ( ...
https://clinicaltrials.gov/show/NCT01227590?order=447

*  An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects - Full...

Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Reverse Transcriptase Inhibitors. Nucleic Acid Synthesis ... An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects. This ... An Open-Label Study of a Once Daily Dose of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected ... Treatment within 30 days prior to Baseline with an investigational drug, agent, and/or vaccine (with the exception of ...
https://clinicaltrials.gov/ct2/show/study/NCT00642291?view=record

*  A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other...

Anti-Retroviral Agents. Reverse Transcriptase Inhibitors. Nucleic Acid Synthesis Inhibitors. Enzyme Inhibitors. Molecular ... and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment- ... Demonstrated sensitivity to etravirine and to at least 1 antiretroviral (ARV) agent in the background regimen, based on the ... Patients will be considered ARV treatment-experienced if they have been on their current stable highly active antiretroviral ...
https://clinicaltrials.gov/show/NCT01422330?order=56

*  Sex, Aging and Antiretroviral Pharmacokinetics - Full Text View - ClinicalTrials.gov

Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. www.aidsinfo.nih.gov. Accessed March ... Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc ( ... Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc ( ... Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc ( ...
https://clinicaltrials.gov/show/NCT00666055?order=74

*  Sex, Aging and Antiretroviral Pharmacokinetics - Full Text View - ClinicalTrials.gov

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. ClinicalTrials.gov processed this record on September 21, 2017. ... Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. www.aidsinfo.nih.gov. Accessed March ... Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc ( ... Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc ( ...
https://clinicaltrials.gov/show/NCT00666055?order=207

*  HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults - Full Text...

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome ... Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any antiretroviral agent). ... HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults. This study ... Subject is receiving, or has received within 90 days prior to screen, any lipid lowering agent, including drugs from the ...
https://clinicaltrials.gov/show/NCT00450580?order=93

*  Kaletra and Viread in Antiretroviral Naïve Patients - Full Text View - ClinicalTrials.gov

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome ... Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in ... Any antiretroviral resistance testing will be performed at Virologic Labs, Inc. Adherence will be assessed at discontinuation ... To assess the efficacy of once daily antiretroviral therapy with Viread 300mg and Kaletra 800mg/200mg in suppressing HIV RNA ...
https://clinicaltrials.gov/ct2/show/study/NCT00679926?view=results

*  Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy - Full Text View - ClinicalTrials.gov

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome ... Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy. The recruitment status of this study is unknown. The ... Drug: First-line Antiretroviral Therapy *Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background ... Drug: First-line Antiretroviral Therapy *Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background ...
https://clinicaltrials.gov/ct2/show/NCT01049685

*  Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens - Full Text View -...

Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Anti-HIV Agents. ClinicalTrials.gov processed this record on ... Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens. Resource links ... Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens. This study has been ...
https://clinicaltrials.gov/show/NCT01006005?order=79

*  Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children - Full Text View - ClinicalTrials.gov

Anti-Retroviral Agents. Anti-HIV Agents. ClinicalTrials.gov processed this record on September 18, 2017. ... Antiviral Agents. Anti-Infective Agents. Nucleic Acid Synthesis Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Third line antiretroviral therapy in this study is defined as an antiretroviral (ARV) regimen in a patient who has failure or ... This is an observational cohort study of virologic and immunologic outcome after at least 48 weeks of third line antiretroviral ...
https://clinicaltrials.gov/show/NCT01225406?order=195

*  The Adult Antiretroviral Treatment and Resistance Study (Tshepo) - Full Text View - ClinicalTrials.gov

Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Anti-HIV Agents. Antimetabolites. Cytochrome P-450 CYP2C9 ... The 'Adult Antiretroviral Treatment and Resistance Study,' hereafter referred to as 'The Tshepo Study,' is the first large- ... The Adult Antiretroviral Treatment and Resistance Study (Tshepo). This study has been completed. ... scale research study of antiretroviral therapy to treat AIDS and HIV infection in Botswana. The Tshepo Study is an open-label, ...
https://clinicaltrials.gov/show/NCT00197613?order=148

*  Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy - Full Text View -...

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. HIV Integrase Inhibitors. Integrase ... Experimental: Antiretroviral Therapy Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in ... Endpoint relating to anti-malnutrition intervention [ Time Frame: 0-48 weeks ]. BMI, weight and body fat assessed by ... Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy (REALITY). This study has been ...
https://clinicaltrials.gov/show/NCT01825031?order=354

*  Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings -...

Anti-Retroviral Agents. Anti-HIV Agents. Antimetabolites. Cytochrome P-450 CYP2C9 Inhibitors. Cytochrome P-450 Enzyme ... Antiviral Agents. Anti-Infective Agents. Nucleic Acid Synthesis Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings ( ... Initiation of antiretroviral therapy: implications of recent findings. Top HIV Med. 2004 Jul-Aug;12(3):83-8. Review. ...
https://clinicaltrials.gov/show/NCT00084136?order=165

*  A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral...

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. HIV Integrase Inhibitors. Integrase ... Patient must have documented failure of certain antiretroviral therapy. *Patient must be on the same antiretroviral therapy for ... A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral ... A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 ...
https://clinicaltrials.gov/show/NCT00293254?order=414

*  Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients - Full Text View - ClinicalTrials.gov

Antiviral Agents. Anti-Infective Agents. Reverse Transcriptase Inhibitors. Nucleic Acid Synthesis Inhibitors. Enzyme Inhibitors ... Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients. This study has been completed. ... The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to ...
https://clinicaltrials.gov/show/NCT00358696?order=96

*  Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy...

Antiviral Agents. Promethazine. Analgesics, Non-Narcotic. Analgesics. Sensory System Agents. Peripheral Nervous System Agents. ... To evaluate the safety of anti-HIV CTL therapy in early stage patients and to verify the safety when combined with antiviral ... Patients in the T cell treatment regimen (regimen 2) receive 2 infusions of ex vivo expanded autologous anti-HIV CTL at 3 and 6 ... Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy ...
https://clinicaltrials.gov/show/NCT00000875?order=189

*  Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl - Full Text View -...

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome ... Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl (ADVANZ-3). This study ... Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl. A Prospective, ... Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir- ...
https://clinicaltrials.gov/show/NCT00532168?order=34

*  Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam - Full Text...

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. ... Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam. This study ... Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection ... Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated ...
https://clinicaltrials.gov/show/NCT00651066?order=43

*  Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects -...

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome ... Indication to start an antiretroviral treatment as long as subject has also a CD4 cell count ≤ 500/mm3 either at screening or ... Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects (ANRS 143). This study has been completed. ... An Open-label Randomised Two-year Trial Comparing Two First-line Regimens in HIV-infected Antiretroviral naïve Subjects: ...
https://clinicaltrials.gov/show/NCT01066962?order=303

*  Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) - Full...

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome ... Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01). This ... Multi-class antiretroviral therapy (ART) is superior to RTV-enhanced ATV in combination with Emtricitabine/Tenofovir DF (FTC/ ... Antiretroviral (ARV) drug-naïve (defined as ≤ 7 days of ARV treatment at any time prior to entry*). ...
https://clinicaltrials.gov/show/NCT00525733?order=128

*  Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART - Full Text View - ClinicalTrials.gov

Anti-Retroviral Agents. Anti-HIV Agents. Cytochrome P-450 CYP2C9 Inhibitors. Cytochrome P-450 Enzyme Inhibitors. Cytochrome P- ... Antiviral Agents. Anti-Infective Agents. Reverse Transcriptase Inhibitors. Nucleic Acid Synthesis Inhibitors. Enzyme Inhibitors ... Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART. This study has been completed. ... Antiretroviral treatment since 6 months, with two nucleoside analogues and one or two protease inhibitors ...
https://clinicaltrials.gov/show/NCT00196612?order=109

*  An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination...

Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Anti-HIV Agents. Cytochrome P-450 CYP3A Inducers. Cytochrome P ... Nevirapine resistance developed in women and infants in the HIVNET 006 and 012 cohorts as a consequence of use of an agent with ... To demonstrate that Nevirapine resistance does not develop in HIV infected patients when used as part of triple antiretroviral ... To demonstrate that Nevirapine resistance does not develop in HIV infected patients when used as part of triple antiretroviral ...
https://clinicaltrials.gov/show/NCT00193947?order=378

*  Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection - Full Text View - ClinicalTrials.gov

Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Anti-HIV Agents. Antimetabolites. Cytochrome P-450 CYP3A ... Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection. This study has been completed. ... For participants with greater than or equal to 300 CD4 cells/ microliter, no prior receipt of antiretroviral therapy. For ... PT or PTT (in the absence of documented anti-cardiolipin antibody) prolonged by greater than 2 seconds. ...
https://clinicaltrials.gov/ct2/show/NCT00001644?term=

*  Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women - Full Text View - ClinicalTrials.gov

Anti-HIV Agents. Anti-Retroviral Agents. Antiviral Agents. Anti-Infective Agents. Cytochrome P-450 CYP3A Inhibitors. Cytochrome ... In other words, we plan to examine whether changes in sex hormones throughout the menstrual cycle affect the amount of anti-HIV ... Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in HIV-Infected Women. This study has been withdrawn prior to ... Subjects must be receiving anti-HIV regimen consisting of tenofovir, emtricitabine, atazanavir, and ritonavir for a minimum of ...
https://clinicaltrials.gov/show/NCT01394133?order=191

*  A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines -...

Anti-Retroviral Agents. Anti-HIV Agents. Cytochrome P-450 CYP2C9 Inhibitors. Cytochrome P-450 Enzyme Inhibitors. Cytochrome P- ... Antiviral Agents. Anti-Infective Agents. Nucleic Acid Synthesis Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Antiretroviral. Antiviral. ARV. TMC278. Efavirenz. Combivir. Truvada. Zidovudine. Lamivudine. Tenofovir disoproxil fumarate. ... A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines. ...
https://clinicaltrials.gov/show/NCT00110305?order=88

Management of HIV/AIDS: The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs in an attempt to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle.Conference on Retroviruses and Opportunistic Infections: The Conference on Retroviruses and Opportunistic Infections (CROI) is an annual scientific meeting devoted to the understanding, prevention and treatment of HIV/AIDS and the opportunistic infections associated with AIDS. Thousands of leading researchers and clinicians from around the world convene in a different location in North America each year for the Conference.Vpx: Vpx is a virion-associated protein encoded by human immunodeficiency virus type 2 HIV-2 and most simian immunodeficiency virus (SIV) strains, but that is absent from HIV-1. It is similar in structure to the protein Vpr that is carried by SIV and HIV-2 as well as HIV-1.Statnamic load test: The Statnamic load test is a type of test for assessing the load carrying capacity of deep foundations which is faster and less expensive than the static load test. The Statnamic test was conceived in 1985, with the first prototype tests carried out in 1988 through collaboration between Berminghammer Foundation Equipment of Canada and TNO Building Research of the Netherlands (Middendorp et al.Adult-onset immunodeficiency syndrome: Adult-onset immunodeficiency syndrome is a provisional name for a newly diagnosed immunodeficiency illness. The name is proposed in the first public study to identify the syndrome.Cytomegalovirus retinitisProtease inhibitor (pharmacology): Protease inhibitors (PIs) are a class of antiviral drugs that are widely used to treat HIV/AIDS and hepatitis caused by hepatitis C virus. Protease inhibitors prevent viral replication by selectively binding to viral proteases (e.HIV-positive people: HIV-positive people are people who have the human immunodeficiency virus HIV, the agent of the currently incurable disease AIDS.Hinduism in Zambia: Zambia is home to 25,000 Hindus.as reported by Hinduism Today, 2003 Hinduism is the third largest religion in Zambia.Nigerian Ports Authority: The Nigerian Ports Authority (NPA) is a federal government agency that governs and operates the ports of Nigeria. The major ports controlled by the NPA include: the Lagos Port Complex and Tin Can Island Port in Lagos; Calabar Port, Delta Port, Rivers Port at Port Harcourt, and Onne Port.Cognitive effects of HIVHIV/AIDS in South African townships: South Africa’s HIV/AIDS epidemic, which is among the most severe in the world, is concentrated in its townships, where many black South Africans live due to the lingering effects of the Group Areas Act. A 2010 study revealed that HIV/AIDS infection in South Africa is distinctly divided along racial lines: 13.Makerere University School of MedicineAddis Ababa Fistula HospitalKaronga District: right|115px|Location of Karonga District in MalawiAIDS-related lymphoma: AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome (AIDS).Resistance mutation: A resistance mutation is a point mutations in virus genes that allow the virus to become resistant to treatment with a particular antiviral drug. The term was first used in the management of HIV, the first virus in which genome sequencing was routinely used to look for drug resistance.Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors: Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors (NRTIs and NtRTIs) began in the 1980s when the AIDS epidemic hit Western societies. NRTIs inhibit the reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of the human immunodeficiency virus (HIV).Kenya Pipeline CompanyTuberculosis managementCombination therapy: Combination therapy or polytherapy is therapy that uses more than one medication or modality (versus monotherapy, which is any therapy taken alone). Typically, these terms refer to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression).Temporal analysis of products: Temporal Analysis of Products (TAP), (TAP-2), (TAP-3) is an experimental technique for studyingAntiviral drug: Antiviral drugs are a class of medication used specifically for treating viral infections. Like antibiotics for bacteria, specific antivirals are used for specific viruses.Tamil Nadu Dr. M.G.R. Medical UniversityFlow cytometry: In biotechnology, flow cytometry is a laser-based, biophysical technology employed in cell counting, cell sorting, biomarker detection and protein engineering, by suspending cells in a stream of fluid and passing them by an electronic detection apparatus. It allows simultaneous multiparametric analysis of the physical and chemical characteristics of up to thousands of particles per second.QRISK: QRISK2 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial fibrillation, diabetes mellitus, and antihypertensive treatment.Prenatal nutrition: Nutrition and weight management before and during :pregnancy has a profound effect on the development of infants. This is a rather critical time for healthy fetal development as infants rely heavily on maternal stores and nutrient for optimal growth and health outcome later in life.PMHC cellular microarray: PMHC cellular microarrays are a type of cellular microarray that has been spotted with pMHC complexes peptide-MHC class I or peptide-MHC class II.Biomarkers of aging: Biomarkers of aging are biomarkers that better predict functional capacity at a later age than chronological age. Stated another way, biomarkers of aging would give the true "biological age", which may be different from the chronological age.Incidence (epidemiology): Incidence is a measure of the probability of occurrence of a given medical condition in a population within a specified period of time. Although sometimes loosely expressed simply as the number of new cases during some time period, it is better expressed as a proportion or a rate with a denominator.

(1/1722) Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.

In an effort to evaluate the potential of non-specific immunotherapy in restoring global immunity, we have examined the clinical tolerance and biological effects of a 6 week administration of the immunomodulator, murabutide, in chronically infected HIV-1 patients. Forty-two subjects, presenting weak immune reconstitution and ineffective virus suppression following long-term highly active antiretroviral therapy (HAART), were randomized to receive, or not, murabutide 7 mg/day on five consecutive days/week. Clinical and immunological parameters were monitored before and after the immunotherapy period. Administration of murabutide was generally well tolerated, although some grade III adverse events, reversible on treatment cessation, were observed. Interestingly, in comparison with pre-inclusion levels, at 1 week after the immunotherapy cycle, only murabutide recipients presented a significant increase in CD4 cells, platelet counts, and in the percentage of patients with undetectable viral loads (<50 copies/mL). Statistical significance between the two groups was only evident with the latter parameter. Some of these clinical changes were maintained even up to 12 weeks after murabutide administration, and were accompanied by an increased ability to mount cellular responses to active immunization with a recall antigen, and by a significant increase in the percentage of patients presenting positive lymphoproliferative responses to the viral antigen gp160. These results warrant further evaluation of extended periods or cycles of murabutide immunotherapy as adjunct to HAART.  (+info)

(2/1722) Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project.

BACKGROUND: To examine demographic and behavioral associations with self-reported health-related quality of life (HRQOL) among persons with HIV infection or AIDS. METHODS: Analysis of interviews with persons > or = 18 years of age reported through routine disease surveillance with HIV infection or AIDS to nine state and local health departments from January 1995 through December 1996. Scales were constructed from validated measures of HRQOL, and mean scores were calculated (lower scores signified poorer HRQOL). Measures of HRQOL included Overall Health, Pain, Physical Functioning, Role Functioning, Social Functioning, Mental Health, Energy/Fatigue, and Cognitive Functioning. Differences in HRQOL were examined by various demographic and behavioral factors, including taking antiretroviral medication. RESULTS: HRQOL data were available for 3778 persons. Factors associated with lower HRQOL scores included older age, female sex, black or Hispanic race/ethnicity, injection drug use, lower education and income, no private health insurance, and lower CD4 count. In multivariate analysis, lower CD4 count was the factor most consistently associated with lower HRQOL. Taking antiretroviral medication was not associated with differences in HRQOL regardless of CD4 count. CONCLUSIONS: Perception of HRQOL varied in a population with HIV infection or AIDS. On most HRQOL measures, lower CD4 count was associated with lower HRQOL. Measurement of HRQOL can assist in understanding the long-term effects of disease and treatment on persons with HIV.  (+info)

(3/1722) HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study.

BACKGROUND: The use and possible effects of factors known to improve outcomes in patients with human immunodeficiency virus associated nephropathy (HIVAN), namely of angiotensin converting enzyme inhibitors (ACE) and antiretroviral therapy, has not been reported for a national sample of dialysis patients. METHODS: We conducted a historical cohort study of the United States Renal Data System (USRDS) Dialysis Morbidity and Mortality Study (DMMS) Wave 2 to identify risk factors associated with increased mortality in these patients. Data were available for 3374 patients who started dialysis and were followed until March 2000. Cox Regression analysis was used to model adjusted hazard ratios (AHR) with HIVAN as a cause of end stage renal disease (ESRD) and its impact on mortality during the study period, adjusted for potential confounders. RESULTS: Of the 3374 patients who started dialysis, 36 (1.1%) had ESRD as a result of HIVAN. Only 22 (61%) of patients with HIVAN received antiretroviral agents, and only nine patients (25%) received combination antiretroviral therapy, and only 14% received ACE inhibitors. Neither the use of multiple antiretroviral drugs (AHR, 0.62, 95% CI, 0.10, 3.86, p = 0.60), or ACE inhibitors were associated with a survival advantage. Patients with HIVAN had an increased risk of mortality (adjusted hazard ratio, 4.74, 95% Confidence Interval, 3.12, 7.32, p < 0.01) compared to patients with other causes of ESRD. CONCLUSIONS: Medications known to improve outcomes in HIV infected patients were underutilized in patients with HIVAN. Adjusted for other factors, a primary diagnosis of HIVAN was associated with increased mortality compared with other causes of ESRD.  (+info)

(4/1722) Polymyositis masquerading as mitochondrial toxicity.

A 66 year old HIV infected male heavy smoker presented with arthralgia, myalgia, and weight loss which was originally ascribed to nucleoside induced mitochondrial toxicity. Despite withdrawal of antiretroviral therapy a proximal myopathy developed. Further investigation excluded malignancy. Polymyositis was diagnosed on muscle biopsy. The patient recovered completely with oral prednisolone. This case highlights the importance of muscle biopsy in HIV infected patients whose myopathy persists despite withdrawal of antiretroviral therapy and the need for thorough investigation of non-specific symptoms in HIV infected patients who are receiving antiretroviral therapy.  (+info)

(5/1722) Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland.

OBJECTIVE: To describe changes in demographic factors, disease progression, hospital admissions, and use of antiretroviral therapy in children with HIV. DESIGN: Active surveillance through the national study of HIV in pregnancy and childhood (NSHPC) and additional data from a subset of children in the collaborative HIV paediatric study (CHIPS). SETTING: United Kingdom and Ireland. PARTICIPANTS: 944 children with perinatally acquired HIV-1 under clinical care. MAIN OUTCOME MEASURES: Changes over time in progression to AIDS and death, hospital admission rates, and use of antiretroviral therapy. RESULTS: 944 children with perinatally acquired HIV were reported in the United Kingdom and Ireland by October 2002; 628 (67%) were black African, 205 (22%) were aged > or = 10 years at last follow up, 193 (20%) are known to have died. The proportion of children presenting who were born abroad increased from 20% in 1994-5 to 60% during 2000-2. Mortality was stable before 1997 at 9.3 per 100 child years at risk but fell to 2.0 in 2001-2 (trend P < 0.001). Progression to AIDS also declined (P < 0.001). From 1997 onwards the proportion of children on three or four drug antiretroviral therapy increased. Hospital admission rates declined by 80%, but with more children in follow up the absolute number of admissions fell by only 26%. CONCLUSION: In children with HIV infection, mortality, AIDS, and hospital admission rates have declined substantially since the introduction of three or four drug antiretroviral therapy in 1997. As infected children in the United Kingdom and Ireland are living longer, there is an increasing need to address their medical, social, and psychological needs as they enter adolescence and adult life.  (+info)

(6/1722) Abnormal contingent negative variation in HIV patients receiving antiretroviral therapy.

The contingent negative variation, an event-related potential related to neural activity in the frontal lobe and basal ganglia, neuropsychological tests and structural MRI were used to examine CNS function and structure in HIV-positive patients receiving antiretroviral therapy. Relative to controls, HIV patients had smaller thalamic volume and reduced late contingent negative variation amplitude that correlated with caudal atrophy. Behaviorally, viremic patients were more impaired than virally suppressed patients and controls on neuropsychological measures of psychomotor speed, selective attention and mental flexibility. These results suggest that antiretroviral therapy may not be effective in protecting cortical and subcortical structures against HIV-related neuropathology, regardless of immune function. However, the benefits of antiretroviral therapy on immune function appear to facilitate neurocognitive performance.  (+info)

(7/1722) The cardiovascular consequences of HIV and antiretroviral therapy.

Antiretroviral therapy has changed the face of the treatment of HIV throughout the world, converting a fatal into a chronic disease. HIV has reached disastrous levels of infection in southern Africa, and increased use of life-saving therapy is being implemented. The antiretrovirals have a variety of metabolic side effects that have been implicated in cardiovascular disease in other populations. This article discusses the impact of HIV on southern Africa, the metabolic and cardiac complications of both HIV and antiretrovirals, and strategies for dealing with drug side effects.  (+info)

(8/1722) Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

Human immunodeficiency virus type 1 (HIV-1) fuses with cells after sequential interactions between its envelope glycoproteins, CD4 and a coreceptor, usually CC chemokine receptor 5 (CCR5) or CXC receptor 4 (CXCR4). CMPD 167 is a CCR5-specific small molecule with potent antiviral activity in vitro. We show that CMPD 167 caused a rapid and substantial (4-200-fold) decrease in plasma viremia in six rhesus macaques chronically infected with simian immunodeficiency virus (SIV) strains SIVmac251 or SIVB670, but not in an animal infected with the X4 simian-human immunodeficiency virus (SHIV), SHIV-89.6P. In three of the SIV-infected animals, viremia reduction was sustained. In one, there was a rapid, but partial, rebound and in another, there was a rapid and complete rebound. There was a substantial delay (>21 d) between the end of therapy and the onset of full viremia rebound in two animals. We also evaluated whether vaginal administration of gel-formulated CMPD 167 could prevent vaginal transmission of the R5 virus, SHIV-162P4. Complete protection occurred in only 2 of 11 animals, but early viral replication was significantly less in the 11 CMPD 167-recipients than in 9 controls receiving carrier gel. These findings support the development of small molecule CCR5 inhibitors as antiviral therapies, and possibly as components of a topical microbicide to prevent HIV-1 sexual transmission.  (+info)



tenofovir


  • The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression. (clinicaltrials.gov)
  • This is a multicenter, randomized, open clinical trial, comparing three parallel groups, to compare the immunological reconstitution and the virological efficacy and safety of three different combinations of antiretroviral therapy given once a day (QD): tenofovir plus emtricitabine plus either efavirenz, lopinavir-ritonavir or atazanavir-ritonavir during 96 weeks in advanced antiretroviral naïve HIV-1 infected patients with less than 100 CD4+ T-cells/mm3. (clinicaltrials.gov)
  • In the context of tenofovir/emtricitabine currently being a reference backbone in first-line antiretroviral regimens, we hypothesise that, in combination with darunavir/r, raltegravir may be an alternative option if its efficacy is non-inferior to tenofovir/emtricitabine. (clinicaltrials.gov)
  • Multi-class antiretroviral therapy (ART) is superior to RTV-enhanced ATV in combination with Emtricitabine/Tenofovir DF (FTC/TDF) with respect to suppression of viral replication. (clinicaltrials.gov)
  • The antiretroviral drugs atazanavir, ritonavir, tenofovir and emtricitabine will be studied. (clinicaltrials.gov)
  • Subjects must be receiving anti-HIV regimen consisting of tenofovir, emtricitabine, atazanavir, and ritonavir for a minimum of 4 weeks prior to the study. (clinicaltrials.gov)
  • This study aims to evaluate the safety and effectiveness of the tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen in antiretroviral therapy (ART)-naive Chinese HIV/AIDS patients. (clinicaltrials.gov)

regimen


  • Patients will be considered ARV treatment-experienced if they have been on their current stable highly active antiretroviral therapy (HAART) regimen for at least 8 weeks prior to screening. (clinicaltrials.gov)
  • Third line antiretroviral therapy in this study is defined as an antiretroviral (ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. (clinicaltrials.gov)
  • Patients in the T cell treatment regimen (regimen 2) receive 2 infusions of ex vivo expanded autologous anti-HIV CTL at 3 and 6 months after beginning AZT/3TC/indinavir therapy. (clinicaltrials.gov)
  • The researchers are involved in a phase II, randomized, two-arm study, comparing the efficacy, safety, and tolerability of open-label ritonavir (RTV)-enhanced darunavir with Truvada to a 5-drug multi-class regimen including truvada, darunavir/ritonavir/maraviroc/and raltegravir on acutely HIV-1-infected, antiretroviral (ARV) drug-naïve men and women. (clinicaltrials.gov)
  • HIV-infected pregnant women who begin taking antiretroviral (ARV) medications in the late stages of pregnancy need an effective medication regimen to reduce the risk of transmitting HIV to their children. (clinicaltrials.gov)
  • The randomized controlled trial is conducted among antiretroviral naive co-infected HIV and tuberculosis patients who receiving rifampicin-based antituberculous regimen fro at least 4 weeks butt not exceed 16 weeks before enrolment. (clinicaltrials.gov)
  • The primary objective of the study is to compare the tolerance and safety between a low-dose Zidovudine (AZT) containing regimen (200 mg BID) and a standard dosage (300 mg BID) in HIV patients initiating a first line antiretroviral therapy. (clinicaltrials.gov)

ritonavir


  • This study will measure the effect of African potato on lopinavir/ritonavir (Kaletra®), a common anti-HIV medicine. (clinicaltrials.gov)
  • This is an open-label (all people involved know the identity of the intervention), single arm, multicenter Phase IV study to evaluate the safety, tolerability, and pharmacokinetics of etravirine (ETR) in combination with antiretroviral (ARV) therapy other than darunavir (DRV) + ritonavir (rtv). (clinicaltrials.gov)
  • This is a Phase IIIB, 48 Week, multicentre, randomized, open-label, parallel group study comparing the safety and efficacy of fosamprenavir plus ritonavir 1400mg/100mg once-daily to fosamprenavir plus ritonavir 700mg/100mg twice-daily, both administered with abacavir/lamivudine 600mg/300mg once-daily in antiretroviral-naive HIV-1 infected adults. (clinicaltrials.gov)
  • Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects. (clinicaltrials.gov)

Emtricitabine


  • To obtain safety and efficacy data for antiretroviral regimens containing emtricitabine in HIV-1 infected pediatric subjects. (clinicaltrials.gov)

evaluate


  • The study is being conducted to evaluate whether African potato, an herbal medicine, can be used together with anti-HIV medicines without affecting the amounts of the anti-HIV medicines in the blood. (clinicaltrials.gov)
  • To evaluate the safety of anti-HIV CTL therapy in early stage patients and to verify the safety when combined with antiviral therapy with zidovudine/lamivudine/indinavir and low-dose interleukin-2 (IL-2). (clinicaltrials.gov)
  • Trial to evaluate steady state pharmacokinetic parameters of nevirapine 150mg/m2 and nevirapine 4 or 7 mg/kg after 4 weeks, and efficacy and safety of the dosing when administered for 48 weeks in antiretroviral drug naïve paediatric patients. (clinicaltrials.gov)
  • Primary objective: To evaluate steady state pharmacokinetic parameters of nevirapine 150mg/m2 in antiretroviral drug naive pediatric patients. (clinicaltrials.gov)

patients


  • The information obtained from this study will tell us if African potato and anti-HIV treatments can be used together to treat HIV infected patients in Africa and other resource poor regions. (clinicaltrials.gov)
  • 50 copies/ml in antiretroviral naïve patients through 48 weeks of therapy. (clinicaltrials.gov)
  • A Phase IV Open Label Investigation of the Efficacy and Durability of Once Daily Antiretroviral Therapy With Kaletra and Viread in Antiretroviral Naïve Patients. (clinicaltrials.gov)
  • 50 copies/ml in antiretroviral naïve patients. (clinicaltrials.gov)
  • 700 persons living with HIV in northeast Oklahoma with four to five antiretroviral naïve patients seen each week. (clinicaltrials.gov)
  • RBT represents an alternative to RMP for HIV infected patients as its half-life is longer and the enzymatic induction effect appears to be less important on the associated antiretroviral therapy (ART) drugs. (clinicaltrials.gov)
  • Objective 2 To demonstrate that resistance to nevirapine does not develop when patients with suppressed HIV RNA discontinue combination antiretroviral therapy which contains nevirapine. (clinicaltrials.gov)
  • A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients. (clinicaltrials.gov)
  • For patients who are starting to take antiretroviral medication (to treat HIV) for the first time, there are now a variety of different medicines which may be taken together as a combination in order to form an effective treatment which suppresses the virus for prolonged periods of time. (clinicaltrials.gov)
  • In this study, the investigators will observe the combination of two licensed antiretroviral medications, ritonavirboosted darunavir(DRV/r) and rilpivirine (RPV), in suppressing virus when given to patients who are commencing treatment for HIV infection for the first time. (clinicaltrials.gov)
  • Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. (clinicaltrials.gov)

Drug


  • The purpose of this research study is to learn about levels of antiretroviral drug levels and response to HIV virus in the genital tract of women who are post-menopausal. (clinicaltrials.gov)
  • The investigators in this study think that the levels of hormones post-menopausal HIV-infected women may have in their bodies may affect the levels of antiretroviral drug, and therefore affect how much HIV virus they have in their bodies. (clinicaltrials.gov)
  • The Tshepo Study is an open-label, randomized study comparing: (1) the rate of development and specific types of drug resistance mutations with various antiretroviral combination therapies to HIV-1C, the subtype of HIV found in southern Africa, and (2) the short and long-term effectiveness of two operational modifications of Directly Observed Therapy (DOT) medication adherence strategies for antiretroviral therapy. (clinicaltrials.gov)
  • The dual combination of boosted darunavir + raltegravir is an innovative treatment option that combines two potent new antiretroviral drugs, one of which belongs to a new drug class (integrase inhibitor). (clinicaltrials.gov)
  • The primary purpose of this study is to examine whether a pharmacokinetics (factors that determine the amount of drug in the body) of anti-HIV drugs change during different phases of the menstrual cycle in women and ultimately result in higher amounts of drug in the body compared with men. (clinicaltrials.gov)

study


  • Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI). (clinicaltrials.gov)
  • This is an observational cohort study of virologic and immunologic outcome after at least 48 weeks of third line antiretroviral therapy. (clinicaltrials.gov)
  • The 'Adult Antiretroviral Treatment and Resistance Study,' hereafter referred to as 'The Tshepo Study,' is the first large-scale research study of antiretroviral therapy to treat AIDS and HIV infection in Botswana. (clinicaltrials.gov)
  • 300 cells/microliter will undergo leukapheresis up to four times - at study entry and about 2, 6 and 12 months after starting antiretroviral therapy. (clinicaltrials.gov)

drugs


  • Since women who have already gone through menopause have different levels of hormones, such as estrogen, than women who are pre-menopausal, the investigators would like to check the levels of antiretroviral drugs in their blood, their genital secretions, and their genital tissue. (clinicaltrials.gov)
  • All participants will be treated with a combination of four antiretroviral drugs: indinavir, zidovudine, lamivudine and nevirapine. (clinicaltrials.gov)
  • Data suggests that women taking drugs to treat human immunodeficiency virus (HIV) have higher amounts of drugs in their body compared with men taking the same dose of anti-HIV drugs. (clinicaltrials.gov)
  • In other words, we plan to examine whether changes in sex hormones throughout the menstrual cycle affect the amount of anti-HIV drugs in HIV infected women. (clinicaltrials.gov)